D
Jazz Pharmaceuticals plc JAZZ
$167.10 $0.390.23% NASDAQ
Recommendation
Prev Close
$166.71
Volume
936,222
Avg Vol (90D)
926,647
Market Cap
$10.13B
Dividend & Yield
--
52-Week Range
$95.49 - $182.99
P/E (TTM)
--
EPS (TTM)
-$6.07
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Mackenzie Financial Corp Raises Holdings in Jazz Pharmaceuticals PLC $JAZZ
12/3/2025 - MarketBeat
3 Healthcare Stocks We're Skeptical Of
12/3/2025 - StockStory Articles
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $13,780,275.00 in Stock
12/3/2025 - MarketBeat
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
12/2/2025 - PR Newswire
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
12/2/2025 - SeekingAlpha
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
12/2/2025 - Seeking Alpha: Transcripts
Jazz Pharmaceuticals (JAZZ, $172.12) RSI Indicator left the overbought zone on December 01, 2025
12/2/2025 - Tickeron - Stocks
Loomis Sayles & Co. L P Trims Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ
12/2/2025 - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Vinva Investment Management Ltd
12/1/2025 - MarketBeat
SG Americas Securities LLC Has $377,000 Holdings in Jazz Pharmaceuticals PLC $JAZZ
11/30/2025 - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Ensign Peak Advisors Inc
11/28/2025 - MarketBeat
JPMorgan Chase & Co. Purchases 59,252 Shares of Jazz Pharmaceuticals PLC $JAZZ
11/27/2025 - MarketBeat
The Bull Case For Jazz Pharmaceuticals (JAZZ) Could Change Following Breakthrough Phase 3 Ziihera Trial Results
11/26/2025 - Simply Wall St
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
11/26/2025 - Zacks Investment Research
Franklin Resources Inc. Sells 52,093 Shares of Jazz Pharmaceuticals PLC $JAZZ
11/26/2025 - MarketBeat
Heather Ann Mcsharry Sells 3,415 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock
11/26/2025 - Ticker Report
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares of Stock
11/26/2025 - MarketBeat
Heather Ann Mcsharry Sells 3,415 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock
11/25/2025 - MarketBeat
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More
11/24/2025 - 24/7 Wall St.
Jazz Pharmaceuticals just downgraded at UBS, here's why
11/24/2025 - The Fly
Intech Investment Management LLC Lowers Stock Position in Jazz Pharmaceuticals PLC $JAZZ
11/24/2025 - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from Analysts
11/24/2025 - MarketBeat
A Look at Jazz Pharmaceuticals's Valuation After Landmark HERIZON-GEA-01 Ziihera Trial Results
11/22/2025 - Simply Wall St
Universal Beteiligungs und Servicegesellschaft mbH Sells 11,225 Shares of Jazz Pharmaceuticals PLC $JAZZ
11/22/2025 - MarketBeat
Bruce Cozadd Sells 18,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock
11/22/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$4.16B
EBITDA (TTM)
$1.36B
EBIT (TTM)
$673.03M
Net Income (TTM)
-$368.48M
Balance Sheet
Total Assets (Q)
$11.36B
Total Debt (Q)
$5.43B
Total Liabilities (Q)
$7.40B
Book Value Per Share (Q)
$65.18
Cash Flow
Cash from Operations (TTM)
$1.39B
Cash from Investing (TTM)
-$1.33B
Cash from Financing (TTM)
-$957.10M
Net Change in Cash (TTM)
-$892.07M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.57
7-Day Total Return
-5.56%
30-Day Total Return
21.53%
60-Day Total Return
30.01%
90-Day Total Return
42.36%
Year to Date Total Return
35.02%
1-Year Total Return
37.37%
2-Year Total Return
37.59%
3-Year Total Return
10.68%
5-Year Total Return
10.66%
52-week Low
Apr 09, 2025 - $95.49
52-week High
Nov 18, 2025 - $182.99
Valuation
Market Cap
$10.13B - Large Cap
Enterprise Value
$13.51B
Price/Sales (TTM)
2.47
Price/Book (Q)
2.56
Dividends and Shares
Shares Outstanding
61.61
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.jazzpharma.com
Phone Number
353 1 634 7800
Address
Waterloo Exchange
Fifth Floor - Waterloo Road
Dublin 4 Dublin, D04 E5W7
Country
Ireland
Year Founded
2003
Business Description
Sector
--
Industry
--
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed